Lilly’s Taltz meets in Phase III for ankylosing spondylitis

In February, Eli Lilly and Co. (NYSE:LLY) reported top-line data from the Phase III COAST-V trial to treat axial spondyloarthritis showing that subcutaneous Taltz ixekizumab met the primary endpoint of a greater proportion of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at week 16 vs. placebo. The company plans to submit regulatory applications for Taltz in the indication this year.

The double-blind, international trial enrolled about 320 patients with axial spondyloarthritis who had never received a biologic disease-modifying anti-rheumatic drug (DMARD). Lilly plans to submit detailed data from COAST-V for presentation at scientific meetings this year...